LamKap Bio gamma AG is a biotechnology company that researches, develops, manufactures and tests fully human bispecific antibodies for cancer immunotherapy, particularly for solid tumors. Its molecules are designed to redirect immune effector cells (macrophages, T cells, natural killer cells) to attack tumor cells and include programs targeting CD47, CD3, CD28 and tumor-associated antigens such as CEA and GPC3.
AI-generated
Offering
Products & services
Industry:Research & Development
✓ Offered
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Research, development and manufacture of bispecific antibodies
Research, development and manufacture of bispecific antibodies for the treatment of malignant tumours; targeted at T cells, macrophages and natural killer cells.
Comparisons
LamKap Bio gamma AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank LamKap Bio gamma AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once LamKap Bio gamma AG has claimed this profile, we'll publish editorial articles and case studies here together.